YB-1 リン酸化の抑制はシスプラチン活性を増強し,胸膜内皮腫における細胞分裂を阻害する
Karin Schelch1,2, Nadine Maach1, Muhammad Hashim1
1Center for Cancer Research, Medical University of Vienna, Vienna, Austria.
British journal of cancer
|September 4, 2025
まとめ
胸腔内皮腫 (PM) のリン酸化YB-1 (冷凍ショックドメインタンパク質YB-1) を標的として,癌細胞の移転と分裂を抑制する. YB- 1 リン酸化を阻害するとシスプラチンと放射線治療の効果が向上する.
科学分野:
- 腫瘍学
- 分子生物学
- 癌 研究
背景:
- 寒冷ショックドメインのタンパク質YB-1は,多発性メソテリオマ (PM) で過剰発現する.
- YB-1の過剰発現は,PMにおける細胞移動とプラチナ抵抗性の増加と相関する.
研究 の 目的:
- PMにおけるセリン102でのYB-1リン酸化の役割を調査する.
- PMにおけるYB-1リン酸化を抑制する治療の可能性を評価する.
主な方法:
- リン酸化YB-1を検出するための免疫ヒストケミストリー,免疫光,および免疫ブロッティング.
- RSK阻害剤 (BI- D1870,LJH685) はYB- 1のリン酸化を阻害するために使用された.
- 治療効果を評価するために,細胞生存性,クローン生成性,移動性,および細胞運命を分析した.
主要な成果:
- 酸化されたYB-1 (セリン102) は,PM細胞系および組織で検出されました.
- YB- 1のリン酸化を阻害すると,核のYB- 1の局所化,細胞活性,クローン生成性,移動が減少した.
- YB- 1 のリン酸化を阻害することで細胞分裂を阻害し,シスプラチンと放射線治療の有効性を高めました.
結論:
- セリン102で酸化されたYB-1は,悪性PMの表型に重要な寄与因子である.
- YB-1リン酸化を阻害することは,PM治療の有望な治療戦略です.
さらに関連する動画
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.8K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.1K
関連する概念動画
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Negative Regulator Molecules
35.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
